236 related articles for article (PubMed ID: 27741201)
1. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Stetson B; Hibbard JU; Wilkins I; Leftwich H
Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
Eke AC; Sheffield J; Graham EM
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
[TBL] [Abstract][Full Text] [Related]
4. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
5. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
6. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Saghafi N; Khadem N; Mohajeri T; Shakeri MT
J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
[TBL] [Abstract][Full Text] [Related]
9. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
Lichter KE; Sheffield J; Graham EM; Eke AC
J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
[No Abstract] [Full Text] [Related]
11. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
12. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
13. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
14. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of cerclage vs. 17 alpha-hydroxyprogesterone caproate for treatment of short cervix.
Keeler SM; Kiefer D; Rochon M; Quinones JN; Novetsky AP; Rust O
J Perinat Med; 2009; 37(5):473-9. PubMed ID: 19492920
[TBL] [Abstract][Full Text] [Related]
16. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
Wood SL; Williams BN; Szychowski JM; Owen J
Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
[TBL] [Abstract][Full Text] [Related]
19. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke AC; Sheffield J; Graham EM
Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
[TBL] [Abstract][Full Text] [Related]
20. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
